Your browser doesn't support javascript.
loading
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
Bethel, M Angelyn; Patel, Rishi A; Merrill, Peter; Lokhnygina, Yuliya; Buse, John B; Mentz, Robert J; Pagidipati, Neha J; Chan, Juliana C; Gustavson, Stephanie M; Iqbal, Nayyar; Maggioni, Aldo P; Öhman, Peter; Poulter, Neil R; Ramachandran, Ambady; Zinman, Bernard; Hernandez, Adrian F; Holman, Rury R.
Afiliação
  • Bethel MA; Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK. Electronic address: angelyn.bethel@dtu.ox.ac.uk.
  • Patel RA; Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK.
  • Merrill P; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
  • Lokhnygina Y; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
  • Buse JB; Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
  • Mentz RJ; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
  • Pagidipati NJ; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
  • Chan JC; Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.
  • Gustavson SM; AstraZeneca Research and Development, Gaithersburg, MD, USA.
  • Iqbal N; AstraZeneca Research and Development, Gaithersburg, MD, USA.
  • Maggioni AP; Italian Association of Hospital Cardiologists (ANMCO) Research Center, Firenze, Italy.
  • Öhman P; AstraZeneca Research and Development, Gaithersburg, MD, USA.
  • Poulter NR; International Centre for Circulatory Health, Imperial College London, London, UK.
  • Ramachandran A; India Diabetes Research Foundation, Chennai, India; Dr A Ramachandran's Diabetes Hospitals, Chennai, India.
  • Zinman B; Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada; Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
  • Hernandez AF; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
  • Holman RR; Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK.
Lancet Diabetes Endocrinol ; 6(2): 105-113, 2018 02.
Article em En | MEDLINE | ID: mdl-29221659
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Sistema Cardiovascular / Diabetes Mellitus Tipo 2 / Receptor do Peptídeo Semelhante ao Glucagon 1 / Hipoglicemiantes Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Sistema Cardiovascular / Diabetes Mellitus Tipo 2 / Receptor do Peptídeo Semelhante ao Glucagon 1 / Hipoglicemiantes Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article